55
Participants
Start Date
February 29, 2004
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2008
Velcade
velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
Idarubicin
I.V., 8, or 10 or 12 mg/m\^2 weekly (days 1, 8, 15, and 22) for 4 weeks
University of Rochester, Rochester
University of Kentucky, Lexington
National Institutes of Health (NIH)
NIH
University of Kentucky
OTHER